Developing alternative routes of immunotherapies with innovative drugs for neurodegenerative diseases.

Learn more about Tiziana   Tiziana Investor Deck   Scientific Presentations and Updates

In the Media

Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar

04 December 2023

NEW YORK, December 4, 2023 -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announces that Matthew Davis, Chief Operating Officer and Chief...

Read more

Tiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple Sclerosis

30 November 2023

NEW YORK, November 30, 2023 -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the company has successfully enrolled and dosed...

Read more

Tiziana Life Sciences to Present Recent Clinical Updates at BIO-Europe in Munich, Germany, November 6-8, 2023

01 November 2023

NEW YORK, November 1, 2023 -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that its Chief Operating Officer and Chief Medical...

Read more

Our Mission

Our mission is to bring breakthrough therapies to patients with the aim of treating Secondary Progressive Multiple Sclerosis, ALS, Alzheimer's, and other CNS indications. Crohn's Disease, lung diseases and optimizing health outcomes.

Learn more

Clinical Candidates

Our major clinical assets are supported by extensive worldwide issued patents and pending patent applications covering composition of matter, formulation technologies, manufacturing processes and disease indications.

Pipeline

Foralumab

Foralumab is a fully human anti-CD3 monoclonal antibody (mAb) for treatment of Crohn’ s Disease and neurodegenerative indications.

Learn more about Foralumab

Anti IL-6 Receptor mAb
(IL-6R:TZLS-501)

We are developing a fully human monoclonal antibody (mAb) targeting the receptor for IL-6 as a potential treatment for lung diseases.

Learn more about Anti IL-6R

Milciclib

Milciclib is the Company’s clinical candidate for the treatment in cancer indications. The company is exploring the combination of milciclib and gemcitibine in NSCLC patients with pan KRAS+ mutations.

Learn more about Milciclib

Clinical Trials

Tiziana is currently conducting clinical development programs for Foralumab, Anti IL-6R and Milciclib

Foralumab

Tiziana reported positive clinical data in a Phase I clinical trial of nasally-dosed Foralumab in healthy subjects in collaboration with Dr. Howard Weiner at Brigham and Women’s Hospital in Boston. Expanded Access program now dosing 6 patients. Phase 2 patient enrollment is expected to begin in 2H 2023 for nasally administered Foralumab for the treatment of Non-active, Secondary Progressive, Multiple Sclerosis.

See more Foralumab clinical trials

Anti IL-6R mAb (TZLS-501)

Manufacturing of clinical supplies for a Phase 1 study is anticipated to be completed in 4Q 2022.

Milciclib

We are exploring a study to evaluate the combination of milciclib and gemcitabine in NSCLC subjects with associated pan KRAS-positive mutations.

See more Milciclib clinical trials

Tiziana Life Sciences is listed on NASDAQ